THE SAFETY AND EFFICACY OF BUFEDIL LONG (BUFLOMEDIL 600MG DELAYED ACTION TABLETS) IN PATIENTS WITH PERIPHERAL ARTERIAL OCCLUSIVE DISEASE (FONTAINE STAGE-II A/B)

The symptoms of peripheral arterial occlusive disease (PAOD) can be attributed to tissue hypoxia. Vasoactive drugs such as buflomedil improve microcirculatory blood perfusion despite the presence of large artery occlusions. In this open study, the safety and clinical efficacy of Bufedil(R) long (buflomedil 600mg delayed action tablets; Abbott Laboratories) were evaluated in 3541 private practice patients with PAOD (Fontaine Stage II a/b). After 8 weeks of therapy, pain-free walking distance increased or doubled for 89.5% of the patients. Claudication pain intensity and the sensation of cold in the lower extremities were reduced in approximately 88% of the patients. Despite the multimorbidity and polypharmacy in this patient population, drug interactions between buflomedil and concurrent medication were not observed. Only 4 patients discontinued the study as a result of adverse events, most of which were mild and transient in nature. Approximately 89% of the patients judged drug compatibility to be good or very good with < 1% reporting poor tolerability.